EPS: As of FY2025 Q2, the actual value is USD -0.43.

Segment Revenue

• General and Administrative Expenses: Increased by $2,299,848 for the three months ended June 30, 2025, compared to the same period in 2024, primarily due to increased legal and accounting fees, salaries, and business development expenses.
• Research and Development Expenses: Increased by $162,406 for the three months ended June 30, 2025, compared to the same period in 2024, primarily due to increased clinical trial activity.

Operational Metrics

• Net Loss: The net loss for the three months ended June 30, 2025, was $6,176,084, compared to $3,632,859 for the same period in 2024.
• Loss from Operations: Loss from operations for the three months ended June 30, 2025, was $6,016,088, compared to $3,553,834 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was $9,409,825, compared to $3,953,639 for the same period in 2024.
• Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided by financing activities was $14,915,048, compared to $10,642,500 for the same period in 2024.

Unique Metrics

• Accumulated Deficit: As of June 30, 2025, the accumulated deficit was $40,182,395, which includes deficits from SkinJect, Inc. and Medicus Pharma Ltd.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue its SKNJCT-003 study and expand clinical trial sites in Europe and the UAE, with a focus on obtaining FDA approval for its products.
• Non-Core Business: The company entered into a definitive agreement to acquire Antev Limited, which is developing Teverelix for prostate cancer patients, expected to close by August 2025.